drugset
drugset / Trial / NCT02305329

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

NCT02305329 ↗

Phase 1 Completed 56 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 25 mg Oral
Subject Opicapone Small molecule 50 mg Oral

Indications

epilepsy